AiCubator

Fostering collaboration for anti-infectives

Often, it is not the lack of groundbreaking ideas that hinders the development of novel, innovative anti-infective drugs. Instead, it is a shortage of funding, development and business experience that limits resources for start-ups and research groups, thereby discouraging the development of new therapeutic options. At AiCuris, we strongly believe in the importance of fostering early-stage projects. Therefore, we are constantly seeking out novel technologies and creative approaches to develop more effective treatments against infectious diseases with high medical needs.

Turning great ideas into reality

To promote early-stage concepts that could lead to the next breakthrough in anti-infectives, AiCuris has launched the AiCubator, an innovative corporate incubator offering hands-on and long-term support (up to 3 years) for research projects. As a leader in anti-infective drug development, AiCuris is dedicated to converting promising ideas into impactful realities. 

 

Currently not open for applications

AiCubator Residents

Universitätsklinikum Hamburg-Eppendorf

There is currently no specific antiviral therapy against BKPyV, which causes severe disease in immunosuppressed patients. The project builds on a well-established workflow from phenotypic screening to mode of action (MoA) and will focus on key experiments to understand cytotoxicity and selectivity in infected primary cells and complex tissues to evaluate the inhibitor for further development.                                                                                  

Universitätsklinikum Erlangen

Researchers from the Institute for Clinical and Molecular Virology at the Universitätsklinikum Erlangen guided by Prof. Dr. Manfred Marschall in cooperation with academic partners at the Friedrich-Alexander University of Erlangen-Nürnberg, discovered unique structural and functional properties of the globular domain of the cytomegalovirus-specific nuclear egress complex (NEC), thereby nominating generally the herpesviral NECs as novel potential targets for therapy strategies against herpesvirus infections.

       

For additional questions and submission of applications please contact us

Contact